CYDY - CytoDyn study of leronlimab for COVID-19 passes first safety review

The independent Data Safety Monitoring Committee ((DSMC)) has completed its first interim analysis of a Phase 2b/3 clinical trial evaluating CytoDyn's (CYDY) leronlimab in severe-to-critical COVID-19 patients. The analysis was performed on data from the first 50% (n=195) of participants.The DSMC recommends that the study continue unchanged.The next safety review will be conducted when enrollment reaches 75% (n=293).Full enrollment (n=390) should be achieved before year-end.

For further details see:

CytoDyn study of leronlimab for COVID-19 passes first safety review